Zepbound and Foundayo Go Telehealth in 2026: What the Lilly–Hims & Hers Deal Means for GLP-1 Prices and Access

Under the agreement, patients can complete a consultation on the Hims & Hers platform, and if a licensed provider decides a GLP-1 medication is appropriate, the prescription can be filled and shipped directly — no detour required. Until now, Reuters reports, patients on that platform could only get Lilly's medicines by leaving the site for LillyDirect, Lilly's own cash-pay pharmacy service. Lilly's USA president Ilya Yuffa put it plainly: any friction in the process increases the chance a patient simply gives up.

Two medicines are covered. Zepbound (tirzepatide) is Lilly's weekly injection, one of the most effective weight loss medications ever approved. Foundayo (orforglipron) is Lilly's once-daily GLP-1 pill, approved by the FDA earlier in 2026 as the first oral GLP-1 for weight management that can be taken any time of day with no food or water restrictions.

One condition of the deal stands out: Hims & Hers has committed not to sell compounded versions or knockoffs of Lilly's obesity drugs. That's a meaningful line in the sand after two years in which compounded GLP-1s — some excellent, some contaminated or mislabeled — flooded the market.

If you're paying out of pocket, the self-pay landscape for brand-name GLP-1s now looks roughly like this on major telehealth platforms: Foundayo starts at $149 a month, Zepbound starts at $299 a month, and Novo Nordisk's medicines — on the same platform since March — start at $149 a month for the Wegovy pill and $199 a month for the Wegovy pen. Starting prices generally apply to the lowest doses, and monthly costs can rise as your dose increases, so ask about the full dose ladder before you commit.

Why is Lilly leaning so hard into self-pay? Because that's where a huge share of the market already is. The company says 40% to 45% of Zepbound sales now flow through self-pay channels rather than insurance — a remarkable figure for a medication that lists for over $1,000 a month through traditional pharmacy channels. With employers trimming GLP-1 coverage for 2027, the cash-pay route is likely to keep growing.

Zepbound remains the heavyweight. In Novo's own REDEFINE 4 head-to-head trial, tirzepatide produced an average weight loss of about 25.5% over 84 weeks — the strongest result of any approved medication.

Foundayo is less powerful but far more convenient. In the 72-week ATTAIN-1 trial, the highest dose produced an average weight loss of about 11.2% across all participants (roughly 12.4% among those who stayed on treatment), versus about 2% with placebo. More than half of patients on the top dose lost at least 10% of their body weight. As a small-molecule pill with no injection, no refrigeration, and no fasting rules, it's an appealing first step for people who would never start a weekly shot.

The honest takeaway: if maximum weight loss is the goal and injections don't bother you, tirzepatide is the stronger tool. If the pill format is what finally gets you to start — and stick with — treatment, Foundayo's results are still life-changing for many patients.

First, check your insurance before paying cash. Some plans still cover GLP-1s with a prior authorization, and a covered prescription usually beats any self-pay price. Second, compare the total monthly cost at your actual dose, not the advertised starting price. Third, remember that the platform matters less than the care behind it: GLP-1s work best with real clinical follow-up — dose adjustments, side effect management, and a plan for maintaining results.

It's also worth understanding what the "no compounded knockoffs" clause is about. The FDA has spent 2026 cracking down on gray-market GLP-1 ingredients and unverified vendors. Legitimate telehealth providers that work with licensed, inspected pharmacies remain a safe route to treatment — but buying mystery peptides from an unregulated website is not, and this deal is partly an effort to pull patients away from that market.

All GLP-1 medications share a familiar side effect profile: nausea, vomiting, constipation, diarrhea, and stomach discomfort are the most common, especially during dose increases. Most of it is manageable with slower titration, dietary adjustments, and, when needed, anti-nausea medication. Both Zepbound and Foundayo carry a boxed warning about thyroid C-cell tumors seen in rodent studies, so they're not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2. People with a history of pancreatitis, significant gallbladder disease, or who are pregnant or planning pregnancy also need an individualized conversation. These are decisions to make with a licensed provider who has reviewed your full health history — not a checkout page.

If this week's news has you thinking seriously about treatment, JoeyMed's licensed providers can help you sort through the options — including high-dose compounded tirzepatide programs from licensed US pharmacies, with clinical oversight, dose titration support, and side effect management built in. Start with a quick online visit at JoeyMed Weight Loss, and a provider will review your health history and goals to recommend a plan that fits — whether that's a GLP-1, a different approach, or a referral for care we don't provide. The best time to compare your options is before you pay for any of them.